Showing results (21-30 of 42) with videos related to
Sort By:
Pageof 5
Development, Growth & Differentiation|November 3, 2020
Light-sheet microscopy-based 3D single-cell tracking reveals a correlation between cell cycle and the start of endoderm cell internalization in early zebrafish developmentAkiko Kondow, Kiyoshi Ohnuma, Yasuhiro Kamei, et al.Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|March 2, 2020
Dabigatran for Japanese Patients with Atrial Fibrillation and Prior Stroke: A Subgroup Analysis of the J-Dabigatran Surveillance ProgramMasahiro Yasaka, Shinichiro Uchiyama, Hirotsugu Atarashi, et al.Journal of Cardiology|March 16, 2019
WITHDRAWN: Effectiveness and safety of long-term dabigatran among patients with non-valvular atrial fibrillation in clinical practice: J-Dabigatran SurveillanceHiroshi Inoue, Shinichiro Uchiyama, Hirotsugu Atarashi, et al.Hypertension Research : Official Journal of the Japanese Society of Hypertension|September 2, 2016
The efficacy and long-term safety of a triple combination of 80 mg telmisartan, 5 mg amlodipine and 12.5 mg hydrochlorothiazide in Japanese patients with essential hypertension: a randomized, double-blind study with open-label extensionJitsuo Higaki, Issei Komuro, Kosuke Shiki, et al.Advances in Therapy|June 25, 2014
Empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, 12-week, double-blind, placebo-controlled, phase II trialTakashi Kadowaki, Masakazu Haneda, Nobuya Inagaki, et al.Advances in Therapy|April 8, 2015
Efficacy and safety of empagliflozin monotherapy for 52 weeks in Japanese patients with type 2 diabetes: a randomized, double-blind, parallel-group studyTakashi Kadowaki, Masakazu Haneda, Nobuya Inagaki, et al.Respiratory Investigation|May 1, 2024
The effect of nintedanib on health-related quality of life in Japanese patients with progressive fibrosing interstitial lung diseases: A subset analysis of the INBUILD trialYoshikazu Inoue, Hideya Kitamura, Masaki Okamoto, et al.Drug Metabolism and Pharmacokinetics|November 15, 2012
Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjectsAkiko Sarashina, Kazuki Koiwai, Leo J Seman, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 7, 2016
Safety and efficacy of faldaprevir in combination with pegylated interferon α-2b and ribavirin in Japanese patients with genotype-1 chronic hepatitis C virus infectionShuhei Nishiguchi, Yasuhisa Urano, Keiko Suzaki, et al.Research and Practice in Thrombosis and Haemostasis|July 27, 2018
Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized studyMasahiro Yasaka, Ippei Ikushima, Akiko Harada, et al.Pageof 5